Kornimate/medical-research-clean huggingface dataset:
suspected deficient activation of vitamin d in patients with secondary hyperparathyroidism

Conditions: Secondary Hyperparathyroidism

Summary: the purpose of this study is to determine if a reduction in the enzyme 1-hydroxylase, which activates vitamin d, is the cause of overactivity of the parathyroid glands (called secondary hyperparathyroidism - normal blood calcium and elevated parathyroid hormone) in a selected group of young patients with normal kidney function.

vitamin d, an essential nutrient, is produced by the skin after sunlight shines on it. vitamin d must then be activated by both the liver and the kidneys to perform its function of maintaining strong bones and helping to prevent heart disease, infection, diabetes and cancer. reduced kidney activation of vitamin d occurs with advanced age and with all kidney diseases. we have identified a small group of patients who appear to have reduced ability of the kidneys to activate vitamin d, even though they are young and do not have chronic kidney disease. in these patients, we are comparing the ability of their kidneys to activate vitamin d to that of healthy controls. to stimulate the kidneys to activate vitamin d, we are giving parathyroid hormone intravenously over 8 hours and collecting blood and urine at baseline, 4 and 8 hours. this type of parathyroid infusion does not cause side effects. the gene that controls this activation is also being studied (by a simple blood test) to look for abnormalities. we are now actively recruiting healthy controls for this study.

Eligibility criteria:
inclusion criteria: * caucasian female * age 40-59 years * serum creatinine \ 60 * serum calcium in the normal range (for u md lab 8.6-10 mg/dl) * parathyroid hormone in the normal range (for u md lab 12-54 pg/ml) * normal 25-hydroxyvitamin d level (30 ng/ml or higher) * for women of childbearing age, non-pregnant (based on negative urine pregnancy test on the morning of the teriparatide infusion) exclusion criteria: * non-caucasian * age under 40 and over 59 years * male * serum creatinine over 1.3 or estimated glomerular filtration rate (gfr) \< 60 * abnormal serum calcium (for u md lab, below 8.6 or above 10 mg/dl) * abnormal parathyroid hormone (for u md lab, above 65 or below 12 pg/ml) * for women of childbearing age, non-pregnant (based on urine pregnancy test on the morning of the teriparatide infusion) * history of bone radiation * history of paget disease of bone * history of bone malignancy or metastases * history of allergy or sensitivity to forteo

Keywords: hyperparathyroidism parathyroid vitamin d vitamin d deficiency
a clinical study of epilepsy localization and prognosis based on pet and resting-state fmri

Conditions: Epileptic Seizure

Summary: 1. by following up the prognosis of surgical patients, the application value of cortex id quantitative analysis in the localization of epilepsy foci was studied. 2. by studying the correlation between autonomic nerve function and epilepsy neural network in epilepsy patients, and analyzing the differences between different epilepsy patients, it can provide more information for judging the prognosis of epilepsy patients.

this study included diagnostic trials and case-control studies, which were observational studies with no intervention. first, the demographic and clinical information of epilepsy patients in the neurology department of xijing hospital were collected, including gender, age, age of onset, course of epilepsy, seizure performance before treatment, seizure frequency before treatment, type and dose of antiepileptic drugs, past history, family history, etc., as well as imaging, eeg, quality of life, and neuropsychological assessment, etc. were collected; secondly, functional magnetic resonance imaging (fmri) and 24-hour holter monitoring were performed on patients who met the inclusion criteria. positron emission computed tomography (pet) images of patients who have undergone or plan to undergo surgery are analyzed; finally, appropriate statistical methods are used for analysis.

Eligibility criteria:
inclusion criteria: meet the diagnostic criteria for epilepsy, * no contraindications for fmri examination. * the patient had no other heart and lung diseases except epilepsy. * patients and their families were aware of this study and signed informed consent. exclusion criteria: * patients with severe infection, cerebrovascular disease, malignant tumor and other systemic diseases that can affect the nervous system, and those with serious dysfunction of the heart, liver, kidney and other organs. * non-epileptic seizures such as syncope and hysteria. * pregnant or lactating women. incomplete clinical data
respiratory disorder during sleep in the pregnancy : a risk factor in gestational diabetese

Conditions: Respiratory Disorder in Patient With Gestational Diabetes

Summary: introduction: the pregnancy brings about physiological and hormonal modifications which cause sleep disorder. the sleeplessness, snoring and a bad sleepquality are frequent during the pregnancy. also a limited breathing airflow happens very often during the pregnancy. the limited airflow causes micro-awakenings that enter in the frame of the high resistances airways syndrome. to our knowledge there is no study about the outcome of micro-awakenings at pregnant women. objectives: to compare the prevalence of the high resistances airways syndrome (rera) in pregnant woman with or without gestational diabetes methods : it is a monocentrical prospective study at pregnant women after the 30th amenorrhea week who consul the gynecologie and obstetrics department of the chu nord in marseille. we are going to compare the breathing disorder during sleep of a control group with a group of women with gestational diabetes. a polysomnograph will be run at the included patients' home. expected results : the physiological and hormonal modifications during the pregnancy could favor nocturnal sleep events (snoring, sahos and rera) and its complications as gravidic hpn and gestational diabetes cause maternal and fœtal and morbidity and mortality. we put the hypothesis that limited airflow in association with micro-awakenings in the rera have a negative impact on the glucose metabolism and favor the gestational diabetes.


Eligibility criteria:
inclusion criteria: pregnant woman in the 3rd quarter of pregnancy (24 to 32 weeks amennorhea). * presenting a gestational diabetes ou not (=controle group) * written and signed consent. exclusion criteria: * twin pregnancy * high blood pressure before pregnancy * diabetes diagnosed before pregnancy * left ventricular ejection fraction below 40% * alcohol consumption (more than 7 glaces/day), drugs of type hypnotic, sedative, opioids * history of gestational diabetes or glucose intolerance * severe cronical respiratory impairment (severe asthma) * creatinine clairance below 60 ml/min
guided creeping technique (gct) in treating gingival recession

Conditions: Gingival Recession

Summary: a novel minimally invasive guided creeping technique (gct) is suggested to treat gingival recessions.

background: coronally advanced flap with connective tissue grafting in a conventional or minimally invasive approaches includes massive soft tissue reflection that reduce soft tissue support and compromise vascularity around the grafted material. in an attempt to preserve soft tissue support, graft stability and maximizing graft protection in treating recession defects the present novel minimally invasive guided creeping technique (gct) is suggested. methods: twelve patients, each contributing a single cairo rt1 gr defect, were treated by guided creeping technique and completed the 6 months follow up. clinical, evaluations were performed and differences among groups were analyzed.

Eligibility criteria:
inclusion criteria: * over 18 years of age * systemically and periodontally healthy * presence of isolated buccal cairo rt1 gingival recessions * an identifiable cej * affected teeth with at least 2mm attached gingiva. exclusion criteria: * smokers * pregnancy * using antiepileptic drugs * using antibiotics for at least 20 days before surgery

Keywords: minimally invasive surgery tunneling techniques gingival recession creeping attachment
gene therapy for wiskott-aldrich syndrome (was)

Conditions: Wiskott-Aldrich Syndrome

Summary: this is a phase i/ii study to evaluate the safety and efficacy of hematopoietic stem cell genetherapy for the wiskott-aldrich syndrome.

this clinical trial is an ex vivo gene therapy trial. the investigational product corresponds to autologous cd34+ cells transduced with a lentiviral vector harboring the human wasp gene.

Eligibility criteria:
inclusion criteria: * males of all ages * severe was (clinical score 3-5) or absence of was protein in peripheral blood mononuclear cells determined by western blotting and flow cytometry * molecular confirmation by was gene dna sequencing * lack of hla-genotypically identical bone marrow or of a 10/10 antigen hla-matched unrelated donor or cord blood after 3 month search * parental, guardian, patient signed informed consent/assent * willing to return for follow-up * only for patients who have received previous allogenic hematopoietic stem cell transplant: * failed allogenic hematopoietic stem cell transplant * contraindication to repeat transplantation exclusion criteria: * patient with hla-genotypically identical bone marrow * patient with 10/10 antigen hla-matched unrelated donor or cord blood * contraindication to leukapheresis * contraindication to bone marrow harvest * contraindication to administration of conditioning medication * hiv positive patient

Keywords: wiskott-aldrich syndrome primary immune deficiency ex vivo gene therapy hematopoietic stem cells
relationship between abnormalities of desmin cytoskeleton, mitochondrial activity and expression of ubiquitin in aspect of pathogenesis of heart failure and prognosis

Conditions: Dilated Cardiomyopathy

Summary: the purpose of this study is evaluation of expression of desmin in cardiomyocytes of patients with idiopathic dilated cardiomyopathy. analysis of relationship between desmin expression and activities of mitochondrium and expression of ubiquitin.


Eligibility criteria:
inclusion criteria: * idiopatic dilated cardiomyopathy, nyha i, ii, iii, iv * dilated left ventricle * ejection fraction below 45% exclusion criteria: * diabetes mellitus * kidney failure (gfr \< 30, creatinine below 2,5 mg/dl

Keywords: heart failure desmin ubiquitin
angiogenesis with positron emission tomography (pet) tracer uptake

Conditions: Angiogenesis; Non-Small Cell Lung Cancer

Summary: purpose: l-\[3-18f\]-α-methyltyrosine (18f-fmt) is an amino-acid tracer for pet. we have conducted a clinicopathologic study to elucidate the correlation of angiogenesis with 18f-fmt and 18f-fdg uptake in the patients with non-small cell lung cancer (nsclc). method: thirty-seven nsclc patients were enrolled in this study, and a pair of pet study with 18f-fmt and 18f-fdg was performed. uptake of pet tracers was evaluated with standardized uptake value. vegf, cd31, cd34, lat1 and ki-67 labeling index of the resected tumors were analyzed by immunohistochemical staining, and correlated with the clinicopathologic variables and the uptake of pet tracers.


Eligibility criteria:
inclusion criteria: * patients who underwent a thoracotomy within 4 weeks after 18f-fmt pet and 18f-fdg pet study * histology is non-small cell lung cancer exclusion criteria: * patient who received neoadjuvant chemotherapy or radiotherapy before surgery * patients who have insulin-dependent diabetes

Keywords: fluorine-18-α-methyltyrosine, positron emission tomography, fluorine-18-fluorodeoxyglucose, lung cancer, angiogenesis the median vegf rate was 45% (range, 10-78%). high expression was seen in 30 patients (81%, 30/37). vegf expression was statistically associated with progressively growing microvessel count.
levels of diagnostic and therapeutic intervention in hospitalized patients

Conditions: Acute Disease

Summary: the objective of this clinical trial is to investigate the impact of implementing a tool for adjusting the level of diagnostic and therapeutic intensity in the clinical practice of physicians attending hospitalized patients. the goal of this clinical trial is to investigate the impact of a tool for adjusting diagnostic and therapeutic intensity in hospitalized patients. the main question it aims to answer is: is there a difference in patient mortality when using the aforementioned tool? the participating physicians will be grouped into 4 groups (5 physicians each). each group will progressively (every 3 months) incorporate the use of the aforementioned tool into their usual clinical practice.


Eligibility criteria:
inclusion criteria: * physician belonging to the non-surgical medical area. * routine clinical activity on a hospital ward caring for hospitalized patients. exclusion criteria: * physician belonging to the oncology-hematology/palliative care hospitalization unit. * refusal to participate in the study.

Keywords: patient care planning decision making advance care planning
the effect of combination of ultrasound and flouroscopy guidance in caudal epidural injections

Conditions: Radiculopathy; Lumbar Disc Herniation; Spinal Stenosis

Summary: the primary purpose of this study is to asses the effect of caudal epidural injection guided by a combination of ultrasound and fluoroscopy on the duration of the procedure and the amount of radiation exposed during the procedure, compared to the application of only fluoroscopy-guided. secondary aims are to reveal the presence of structural variations that prevent injection by examining the morphology of the sacral hiatus by ultrasonography.

the study was designed as prospective, randomized, controlled trial. the patients who meet the eligibility requirements will be randomized into two groups in a 1:1 ratio to fluoroscopy and ultrasound+fluoroscopy. before the procedure, all patients will be scanned with ultrasonography to examine the caudal region morphology. processing time will be recorded during injection. "fluoroscopy time" (sec) and "kerma-area product" (μgy) automatically measured by the fluoroscopy device will be used to evaluate the radiation exposure. pre-procedural visual analogue scale (vas) scores and oswestry disability index (odi) values were noted all the patients.

Eligibility criteria:
inclusion criteria: * aged\> 18 years * participation in the study voluntarily * diagnosis of radiculopathy caused by spinal stenosis or disc herniation after physical examination and imaging (bt or mri) exclusion criteria: * cauda equina syndrome or rapidly progressing neurological deficit * previous spine surgery * local site infection * history of allergy to local anesthetic and contrast agents * acute or chronic unstable medical disease * psychiatric illness * anticoagulant therapy

Keywords: caudal injection ultrasound fluoroscopy
activation of polyamine catabolism in patients with acute pancreatitis

Conditions: Pancreatitis; Polyamines

Summary: background: polyamines are essential compounds in all mammalian tissues. if tissue spermidine/spermine levels, however, dramatically decrease, the cellular survival is severely endangered. transgenic animals, where the homeostasis of cellular polyamines can be disturbed and tissue spermidine/spermine levels are decreased, acute pancreatitis evolves, indicating pancreas to be one of the most vulnerable organs for tissue polyamine catabolism. on the other hand, our own data suggests that also in other models of acute experimental pancreatitis pancreatic polyamines are changed depending on the severity of pancreatitis in such a way that the more severe pancreatitis the lower are the pancreatic polyamine levels. minor changes were observed also in rats undergoing sham operation only. in addition of pancreatic enzymes, inflammatory mediators are also involved in the pathophysiology of the disease. crp, il-6, il-8, il-10 and procalcitonin are useful in predicting the severity of the disease, combination of il-6 and il-10 at admission can predict organ failure with sensitivity of 95 %, specificity of 88 %. hypothesis: similar to experimental pancreatitis, blood polyamine changes are associated with acute pancreatitis also in the man. these changes are dependent on the severity of pancreatitis, but not on the etiology of pancreatitis. the changes are specific to acute pancreatitis compared with other intra-abdominal emergencies. the changes observed return to baseline during recovery. furthermore, we assume that blood polyamine negatively correlates with il-6, il-8, and procalcitonin, and positively with il-10.


Eligibility criteria:
inclusion criteria: * patients who are diagnosed as acute pancreatitis. * patients who are diagnosed as either of gallstone, duodenal ulcer or bleeding, gastric ulcer or bleeding, irritable bowel syndrome, hernia, diverticulitis, retrocecal appendicitis with non-pancreatic acute abdominal pain. exclusion criteria: * patients who underwent operation * patients who underwent recurrent acute pancreatitis

Keywords: pancreatitis polyamine cytokine
prostate cancer imaging with radioactive tracer and ultrasound detector compared to mri and prostascint

Conditions: Prostate Cancer

Summary: this is a small study to determine if probe, similar to an ultrasound probe, can detect prostate cancer more specifically than other imaging studies in patients with a positive prostate cancer biopsy.


Eligibility criteria:
inclusion criteria: * primary prostate cancer proven by sextant prostate biopsy * transrectal ultrasound (trus)-guided prostate biopsy within 6 months of study enrollment * sufficient time period to complete imaging protocol and 5-7 day safety followup assessment without other therapeutic intervention * in the judgement of principal investigator, patient able to provide informed consent and be compliant with protocol requirements * ecog status of 0 or 1 pt \> 18 yrs of age exclusion criteria: * definitive or concomitant therapeutic intervention within the interval of study intervention * prior pelvic therapeutic radiation * active malignancy or therapy for malignancy with 6 months other than basal or squamous cell carcinoma of the skin * pt received radiopharmaceutical which was within 5 half-lives at the time of studying imaging * known history of human-anti-murine-antibodies or known allergic reaction to previously received murine based products

Keywords: biopsy proven primary prostate cancer
adrenal project: clinical and epidemiological characterization of adrenocortical carcinoma in a brazilian cohort

Conditions: Carcinoma Adrenal; Carcinoma, Adrenocortical Recurrent

Summary: this is a retrospective observational cohort study. the clinical, pathological and treatment data of participants identified with adrenocortical carcinoma from the year 2000 onwards will be evaluated. participants recruited for this study will be identified at the participating sites.

adrenocortical carcinoma is one of the rarest neoplasms in the world. in brazil, especially in the south and southeast regions, the incidence of adrenocortical tumors is around 15 times higher than in the rest of the world, largely attributed to the significant prevalence of the tp53-r337h germline mutation in this population. in view of this characteristic, the clinical and epidemiological characterization of this cohort, as well as the identification of prognostic factors, is of great importance. the starting point for this project was the cohort of 66 participants with adrenal carcinoma included in the final project of the medical residency in clinical oncology at the a.c. camargo cancer center by student rafael haikal dos santos abduch. the aim is to include case studies from the main brazilian site that have followed up and treated patients with adrenal carcinoma.

Eligibility criteria:
inclusion criteria: * participants over 18 years old; * diagnosis of adrenocortical carcinoma with at least one clinical evaluation at the reference institution; * initial diagnosis or recurrence from the year 2000 onwards. exclusion criteria: * participants with insufficient clinical or pathological data in the medical records.

Keywords: carcinoma adrenocortical
neoadjuvant therapy with trastuzumab and chemotherapy and the resultant pathologic complete response observed in her2 positive breast cancer;a systematic review

Conditions: HER2+ Breast Cancer

Summary: the goal of this systematic review is to assess the effectiveness of neoadjuvant chemotherapy and trastuzumab in achieving pathological complete response (pcr) in patients with her2-positive breast cancer. the main questions it aims to answer are: * what is the overall rate of pathological complete response (pcr) in her2-positive breast cancer patients treated with neoadjuvant chemotherapy and trastuzumab? * are there any variations in the definition of pcr among the included trials? participants in the selected clinical trials were her2-positive breast cancer patients with non-metastatic operable, locally advanced, or inflammatory breast cancer. the main tasks participants were asked to do and the treatments they received are as follows: * undergo neoadjuvant chemotherapy: participants received chemotherapy treatment before their primary surgery. * receive trastuzumab: participants were administered trastuzumab, a targeted therapy for her2-positive breast cancer. researchers would compare the group of participants receiving neoadjuvant chemotherapy and trastuzumab to other groups, if present, to see if there are differences in the rates of pathological complete response (pcr) or other effects.

this systematic review aimed to assess the effectiveness of neoadjuvant chemotherapy and trastuzumab in achieving pathological complete response (pcr) in patients with her2-positive breast cancer. the researchers identified nine clinical trials that met the inclusion criteria. these trials included patients with non-metastatic operable, locally advanced, or inflammatory breast cancer, and they evaluated the pcr as the primary or secondary endpoint. the trials utilized different chemotherapy and targeted therapy regimens, along with varying dosages of trastuzumab. the primary outcome of interest was the pcr rate, while other survival outcomes were not analyzed. among the 1,209 patients who received neoadjuvant chemotherapy and trastuzumab, the overall pcr rate was found to be 42%. the review provided detailed information about the design of the selected trials, patient characteristics, disease staging, her2 status, administered treatment regimens, and primary/secondary endpoints. it also mentioned slight variations in the definition of pcr across the trials.

Eligibility criteria:
inclusion criteria: * patients with breast cancer that was found to be her2 positive were included * only patients who underwent neoadjuvant therapy were included * all cytotoxic chemotherapy regimens were considered eligible for this systematic review given that the same drugs were given at the same dose in every trial. exclusion criteria: * patients with metastatic breast cancer were not included in the systematic review * results from adjuvant therapy were excluded from this study. * only the most recent publication (and the most informative) was included if numerous publications of the same trial were retrieved or if there was a case mix between publications.